Novo Nordisk sets Wegovy self-pay prices at $349 for pens and $399 for the high dose
The published cash prices give uninsured and non-covered patients a posted number to plan around, while the $25 figure depends on commercial coverage and program rules.
Novo Nordisk's published self-pay prices for Wegovy (semaglutide) now list at $349 a month for the 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg pens, and $399 a month for the Wegovy HD 7.2 mg pen, according to the company's price guide [2]. The Wegovy pill is listed at $149 a month for 1.5 mg, $199 a month for 4 mg, and $299 a month for the 9 mg and 25 mg doses [1][2].
A limited-time offer for new patients sits below those numbers. Patients new to the Wegovy Savings offer or to NovoCare Pharmacy pay $199 a month for the 0.25 mg and 0.5 mg pens, for two monthly fills, through December 31, 2026. After that, those two doses are listed at the standard $349 a month [1][2]. Novo Nordisk describes the pill prices as its standard self-pay offer [2].
For people with commercial insurance, the savings offer lists a copay of as little as $25 a month, subject to a maximum savings of $100 a month. Government beneficiaries are excluded from that offer [1][2]. The price guide says self-pay pricing is available for local pharmacy pickup with a savings offer or through home delivery [2].
The guide defines one month of pen supply as one box of four pens and one month of pills as one bottle of 30 tablets [1][2]. Novo Nordisk states that it reserves the right to modify or cancel these programs at any time [1][2].
The price guide does not include a list price figure for Wegovy, and it does not say how many patients pay cash rather than using insurance. Whether other pharmacies match these self-pay prices has not been reported. Prices for competing GLP-1 medicines are not part of the Wegovy guide, so no direct comparison is available from it [2].
Why it matters for patients
The posted $349 and $399 figures are the amounts a patient without insurance coverage, or whose plan does not cover Wegovy, would face before any other discount. Because Novo Nordisk publishes these numbers by dose, patients and prescribers can see that the 7.2 mg high-dose pen costs $50 a month more in cash than the lower pen doses [2].
The as-little-as-$25 copay is not automatic. It requires commercial insurance, is capped at $100 a month in savings, and excludes people covered by government programs such as Medicare or Medicaid [1][2]. A person whose plan pays little or nothing toward the drug could still owe the self-pay price. The published materials do not say how the savings offer interacts with a plan that covers only part of the cost.
Supply definitions also matter at the pharmacy counter. A "month" of pens means a box of four, and a "month" of pills means a bottle of 30 tablets, so the monthly price assumes that quantity and that dosing schedule [1][2]. The company can change or end these prices and offers, which means the numbers a patient sees now are not locked in [1][2].
What happens next
The introductory $199-a-month pricing for the 0.25 mg and 0.5 mg pens runs for two monthly fills through December 31, 2026, after which those doses revert to $349 a month unless the company changes the program [1][2]. Novo Nordisk has not disclosed what, if anything, will replace that offer, and it has not said whether the $349 and $399 standard prices will hold beyond that date [1][2].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.